Loading...
•
Mar 31, 2021
Arvinas Q1 2021 Earnings Report
Arvinas reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Key Takeaways
Arvinas reported a net loss of $41.0 million for the quarter ended March 31, 2021, compared to a net loss of $21.7 million for the quarter ended March 31, 2020. Revenues were $5.5 million for the quarter ended March 31, 2021, compared to $6.2 million for the quarter ended March 31, 2020. As of March 31, 2021, cash, cash equivalents and marketable securities were $651.3 million.
Presented preclinical data of ARV-110 and ARV-471 at AACR.
Cash, cash equivalents and marketable securities were $651.3 million as of March 31, 2021.
Research and development expenses were $34.9 million for the quarter ended March 31, 2021.
Revenues were $5.5 million for the quarter ended March 31, 2021.
Forward Guidance
Arvinas expects its cash, cash equivalents, and marketable securities will be sufficient to fund its planned operating expenses and capital expenditures into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...